Posted on

Numinus Announces Compassionate Access Trial of Psilocybin-Assisted Psychotherapy for Substance Use Disorders

Open-label clinical trial will evaluate and refine best practices for the delivery of psilocybin-assisted psychotherapy for participants with tobacco, stimulant, alcohol, and/or opioid disorders

VANCOUVER, BC, Nov. 18, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of solutions centred on the research, development, and delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapies, has announced it will undertake a compassionate access clinical trial of psilocybin-assisted psychotherapy for substance use disorders. This study will enable the company to implement, test, and refine optimal protocols for the use of psilocybin-assisted psychotherapy for participants with a range of substance use disorders and will be conducted in collaboration with Syreon Corporation, a global contract research organization with expertise in conducting clinical trials across a broad range of chronic and complex diseases. The study will involve an initial 30 participants who will take part in a motivational enhancement psychedelic psychotherapy intervention with psilocybin.

According to Health Canada’s Special Access Programme, compassionate access single-arm open-label clinical trials can be incorporated into drug development planning to “meet the needs of patients who are not eligible for enrollment in other pivotal trials” and is one of Health Canada’s preferred means for patients to access drugs that are not yet available on the market.

“Research has already demonstrated great promise for psilocybin-assisted psychotherapy as a treatment for certain substance use disorders,” said Chief Medical Officer, Dr. Evan Wood. “But, psilocybin is still illegal in Canada. This compassionate access trial will begin to address the hurdle of public accessibility, while allowing us to evaluate service delivery models and study the impacts of psilocybin-assisted psychotherapy as an adjunct to standard of care treatments for substance use disorders.”

The study builds upon a growing body of research demonstrating psilocybin-assisted psychotherapy’s efficacy as a novel treatment for specific substance use disorders. A pilot study focusing on tobacco addiction at Johns Hopkins University found that 12 months after psilocybin therapy sessions, approximately 70 percent of participants remained completely abstinent from smoking and approximately 90 percent rated their psilocybin experience as among the most personally meaningful experiences of their lives. A study of psilocybin-assisted psychotherapy for alcohol use disorder at New York University has also demonstrated major reductions in alcohol use.

The evolving international regulatory landscape has opened the door to accessibility of psilocybin-assisted psychotherapy, and Numinus’s compassionate access trial is expected to contribute to continued interest in expanding access.

“The tides are turning for the regulated use of psilocybin, as witnessed earlier this month in the United States. A yes vote for Measure 109 in Oregon permits licensed service providers to provide psilocybin-assisted psychotherapy, and Health Canada has an ongoing provision of exemptions for psilocybin for medical use,” said Founder, CEO, and Chair, Payton Nyqvest. “By increasing access through a compassionate access trial, we hope to help lead the way to regulation in Canada through our implementation science approach which will provide critical outcome and safety data to health regulators.”

Numinus’ compassionate access trial is the first in a series of planned projects and partnerships aimed at expanding access to MDMA for treatment of PTSD and psilocybin for treatment of substance use disorders. These implementation science initiatives will allow the company to refine clinical protocols and strategies for when these medications are approved for widespread use by regulating bodies.

ON BEHALF OF THE BOARD OF NUMINUS WELLNESS INC.
Payton Nyquvest
President, Chief Executive Officer and Chair

About Numinus
Numinus Wellness Inc. (TSXV: NUMI) is a mental health and wellness company creating an ecosystem of solutions centred around safe, evidence-based, accessible psychedelic-assisted psychotherapy to help people heal and be well.

Numinus Health is dedicated to delivering innovative treatments to address physical, mental, and emotional health, through clinics and virtual services.

Numinus R&D is conducting implementation science and leveraging partnerships to beta-test and refine optimal models of psychedelic-assisted psychotherapy delivery, setting the stage for approved routine use in mental health and wellness care.

Numinus Bioscience is focused on developing testing methods and effective formulas for the evolving psychedelics space. Health Canada licences, scientific expertise, and new technologies facilitate ongoing innovation, and high-throughput contract services generate established revenue.

Learn more at numinus.ca, and follow us on Facebook, Twitter, and Instagram.

About Syreon
Syreon provides a full suite of adaptive clinical trials, health economics and outcomes research ensuring safe, effective and value-driven clinical use of innovative therapies in more than 40 countries.

Syreon partners with an elite portfolio of global pharmaceutical corporations and early-stage biotech companies to speed the evaluation of new therapies and improve health outcomes. Its expert research services identify precise therapeutic needs, rapidly evaluate new health interventions, monitor clinical use and define optimal economic value in today’s competitive health environment.

Syreon scientists have contributed to many groundbreaking innovations, from the first blockbuster signal inhibitors, chimeric and humanized monoclonals, recombinant human proteins and companion diagnostics to the developing fields of immuno-oncology, stem cell therapeutics and other recent initiatives in precision medicine.

Syreon’s head offices in North America and Europe coordinate an international network of regional offices and expert research teams providing personal support and professional coordination to clients, investigators, providers, purchasers and payers. Our services through all phases of study planning, operation, analysis and reporting ensure safe, effective and value-driven clinical use.

www.syreon.com

Forward Looking Statements
This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, municipal, local or other licences and any inability to obtain all necessary governmental approvals licences and permits to operate and expand the Company’s facilities; regulatory or political change such as changes in applicable laws and regulations, including federal and provincial legalization, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the Company’s limited operating history and lack of historical profits; reliance on management; the Company’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

For further information: Dana Harvey, Chief Communications Officer, media@numinus.ca

Posted on

Nova Mentis Life Science Announces Receipt of Pilz Shareholder Approval

November 18, 2020 6:00 am Published by 

Novamentis

Vancouver, British Columbia – November 18, 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that, further to its news release dated November 2, 2020, the shareholders of Pilz Bioscience Corp. (“Pilz“) have approved the amalgamation agreement between Pilz and 1271642 B.C. Ltd. (“Nova Subco“), a wholly-owned subsidiary of the Company, pursuant to which the Company will acquire all of the issued and outstanding common shares in the capital of Pilz (the “Transaction”).

Pilz is a research driven biotechnology company that aims to develop medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs.  Pilz’s focus is on Autism Spectrum Disorder (ASD), and its initial research has centred on developing a unique and proprietary system for diagnosing and treating ASD, with first-in-class psilocybin-based therapeutics.

The Pilz research and development program is led by the distinguished Dr. Marvin S. Hausman MD. Dr. Hausman is an Immunologist and Board-Certified Urological Surgeon with more than 30 years of drug research and development experience with various pharmaceutical companies, including Bristol-Myers International, Mead-Johnson Pharmaceutical Co., E.R. Squibb, Medco Research, and Axonyx.

Dr. Hausman is well-supported in his research efforts at Pilz, by Dr. Julia Perederiy, an established research neuroscientist, and Dr. Viviana Trezza, Head of Pharmacology, Roma Tre University, Rome, Italy. The goal of both scientists is to investigate the brain mechanisms underlying functional and dysfunctional socio-emotional behavior, especially in Autism Spectrum Disorder (ASD).

The Transaction
The Transaction will be effected by way of a “three-cornered” amalgamation (the “Amalgamation“), in which: (a) Nova Subco will amalgamate with Pilz to form an amalgamated company (“Amalco“); (b) all issued and outstanding shares of Pilz will be exchanged for common shares of the Company on a 1:1 basis; and (c) Amalco will become a wholly-owned subsidiary of the Company and shall be renamed Pilz Bioscience Corp. upon closing.

Pursuant to the Transaction, Nova will acquire 100% of the issued and outstanding shares of Pilz at a ratio of one Nova common share (each, a “Nova Share”) for every one Pilz common share (each, a “Pilz Share”). Upon closing of the Transaction, it is expected that Nova will issue 50,006,332 Nova Shares to the shareholders of Pilz. Of these shares, 12,250,000 are subject to a voluntary pooling agreement whereas certain Pilz shareholders have agreed to resale restrictions on their Nova Shares: 20% to be released upon closing of the Transaction, a further 40% to be released three (3) months following closing, and the remaining 40% to be released six (6) months following closing.

In connection with the Transaction, Dr. Marvin S. Hausman MD shall be appointed Chairman of Nova’s Scientific Advisory Board and Amalco’s Chief Medical Officer.

About Pilz Bioscience Corp.
Pilz Bioscience Corp. (“Pilz”) is a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs. The initial focus is on Autism Spectrum Disorder (ASD). The company intends to leverage a unique systems-level scientific approach that integrates inflammation, oral/gut/brain axis, and behavior. Pilz aims to lead the global effort in design of effective and comprehensive diagnostic/monitoring programs and first-in-class therapeutics.
https://pilzbioscience.com/

About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. (formerly Liberty Leaf Holdings Ltd.) is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, an Okanagan BC based, Health Canada Standard Licensed facility focused on the cultivation of premium, small batch Kush dominant cultivars.

For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca

On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.

Phone: 778-819-0244
Toll Free: 1-833-542-5323

Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

FacebookTwitterLinkedInEmailShare
Posted on

BETTER PLANT LAUNCHES NEW JUSU ECOMMERCE SITE

Vancouver, B.C. – November 17, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce the launch of the new Jusu eCommerce site at getjusu.com and the Jusu product rebrand following the Company’s recent acquisition of Jusu, which produces a line of plant-based products for consumption, body and personal care.

“I am very excited about the launch of the new getjusu.com website,” says Gabriel Villablanca, Director of eCommerce for Better Plant. “It makes it easy for customers by giving them a one-stop-shop to tap into the vast catalogue of plant-based wellness products that Jusu Wellness has to offer.”

The new website has launched with an initial inventory of 44 newly branded plant-based products and the Company plans to roll out another 55 products from the Jusu catalogue over the next six months.

The site offers a mobile first experience that is designed to increase conversions and improve the customer experience. This is complemented by improved navigation and a customer-centric approach that creates a seamless shopping experience across Jusu’s entire catalogue. It is also equipped with enhanced video features to make for a visually engaging experience.

“We plan to continue to iterate the online experience of the website so that we can create what feels like a partnership between our products, and our amazing customers,” added Villablanca.

The Company will also soon be launching incentives programs, including a rewards program that earns customers points and access to exclusive content. Additional bundles of the most popular products and scents will become available to give customers a chance to try an assortment of similar products together.

 

About Jusu Wellness Inc.

Jusu Wellness Inc. is a wholly owned subsidiary of Better Plant and it owns and operates Jusu, a full spectrum wellness brand with a mission to enlighten consumers to the protective and effective properties of plant-based products. Jusu is committed to making pure, organic, plant-based products for consumption, body, and personal care. This includes one JUSU Bar location in Victoria, BC and brick-and-mortar juice bar franchise opportunities as well as an extensive direct-to-consumer product offering including cold-pressed juices, skin care and body products, aromatherapy, and home cleaning lines. Jusu is fully dedicated to offering consumers healthier alternatives to currently available chemical-based skin care, edible, and beverage products.

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of our products.  Its  all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients.  It has an extensive catalogue of over 400 proprietary product formulas.  Better Plant currently has over 60 plant-based products for sale through eCommerce or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 52% of NeonMind Biosciences Inc. NeonMind has a line of medicinal mushroom coffees, and Health Canada has approved NeonMind’s preclinical trial to support research using psilocybin as a treatment for weight loss. NeonMind has filed 5 U.S. provisional patents to protect its psychedelic research.

For more information about Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

Go to www.getjusu.com to buy Jusu products.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com 

1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

Pilz BioScience Senior Team Members To Participate In Upcoming Microdose Conference

November 17, 2020 6:00 am Published by 

Novamentis

Vancouver, British Columbia – November 17, 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that senior members of the Pilz Bioscience Corp. (“Pilz”) team will be participating in the upcoming “The Mushroom Conference: A Molecular Masterclass” hosted by Microdose Psychedelic Insights and The Conscious Fund, November 20-22, 2020.

Pilz has signed on as a silver sponsor of the conference and Pilz Chairman and Chief Scientific Officer, Dr. Marvin S. Hausman MD, will be a keynote speaker at the event.  Dr. Hausman will be delivering a presentation entitled, “A Strategy For Making Psilocybin Clinical Trials More Successful”.  Therein, based upon his many years of experience navigating the regulatory framework of the drug development and drug discovery process, Dr. Hausman will elaborate on various aspects of the clinical trial process.

Dr. Julia Perederiy, PhD, Pilz Lead Scientist, will also be participating in a panel discussion of the science of psychedelics entitled, “Psilocybin Science: Looking Back and Moving Forward”. The conversation will focus on clinical applications of psychedelic therapeutics, including their potential to address depression, anxiety, and social isolation common in Autism Spectrum Disorders.

NOVA’s pending acquisition of Pilz is subject to requisite regulatory approval, as applicable, and receipt of requisite approval of Pilz shareholders.

About Pilz Bioscience Corp.
Pilz Bioscience Corp. (“Pilz”) is a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs. The initial focus is on Autism Spectrum Disorder (ASD). The company intends to leverage a unique systems-level scientific approach that integrates inflammation, oral/gut/brain axis, and behavior. Pilz aims to lead the global effort in design of effective and comprehensive diagnostic/monitoring programs and first-in-class therapeutics.
https://pilzbioscience.com/

About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. (formerly Liberty Leaf Holdings Ltd.) is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, an Okanagan BC based, Health Canada Standard Licensed facility focused on the cultivation of premium, small batch Kush dominant cultivars.

About Microdose Psychedelic Insights
Microdose Psychedelic Insights aims to unlock the potential of psychedelics through Industry events, market intelligence, original, evidence-based content, strategy and community. We enable and empower society at large to make better, more mindful decisions about psychedelics and its intersection with healthcare, medicine and personal growth. We work with the industry’s most influential stakeholders, some of the world’s best-known brands and an unrivalled network of scientists, researchers, analysts, innovators, investors and advisors.

https://microdose.buzz

For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca

On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Posted on

Silo Wellness Announces the First-of-Its-Kind U.S.-Legal Psychedelic Wellness Nature Retreat in Oregon

SPRINGFIELD, Ore., Nov. 13, 2020 (GLOBE NEWSWIRE) — Oregon’s Silo Wellness (“Silo”), an early mover in the psychedelic mushroom space is pleased to announce that it is organizing a ketamine-assisted wellness retreat in Oregon under the care of Dr. Matthew Hicks, ND, MS. This will add to the existing psilocybin operations in Jamaica, where Silo currently has mushroom and truffle cultivation, as well as multiple psychedelic retreat offerings. In 2019, the company announced its patent-pending psilocybin nasal spray it developed in Jamaica.

Following the landmark passing of Oregon’s Measure 109 authorizing the Oregon Health Authority to permit licensed service providers to administer psilocybin in therapeutic settings (after a two-year rulemaking development period), Silo has positioned itself with a unique alternative to the brick-and-mortar ketamine clinic, similar to the psychedelic retreats it offers in Jamaica.

“We can take our Jamaica psilocybin retreat protocols and use them in Oregon ketamine retreats and then later in Oregon psilocybin retreats once that program is implemented,” explained Silo Director of Science pharmacologist Parag Bhatt, PhD. “This US-based psychedelic retreat model would allow the addition of psilocybin and other natural psychedelics if and when other states come online, similar to the medical marijuana legalization trajectory that began back in 1995 in California.”

The Oregon ketamine-assisted wellness retreat establishes a United States base to meet the needs of those suffering from emotional, spiritual or psychological pain but unable to make a trip to Jamaica to experience legal psilocybin. A short flight from Seattle and San Francisco, and less than a 2.5-hour drive from Portland, Silo’s first Oregon retreat will allow qualifying participants to experience Ketamine-assisted wellness benefits alongside nature. “While ketamine clinics are a convenient and necessary choice for many, psychedelic-enhanced therapy depends a lot on mindset and setting,” said Silo medical advisor and AIMS Clinic of Seattle co-founder Sunil Aggarwal, MD, PhD, FAAPMR. “Traditionally, however, the natural setting has been preferred for those experiencing non-ordinary states of consciousness.”

Silo has engaged experienced ketamine-assisted psychotherapy (KAP) clinic operators Drs. Aggarwal and Leanna Standish, ND, PhD, LAc, FABNO to help develop the screening, retreat agenda, and protocols, as well as research outcomes.

“We welcome the opportunity to activate on this aspect of our business,” stated Douglas Gordon, Silo’s Chief Executive Officer.   “Silo moved early precisely to be in pole position to deliver on these types of experiences and with the passing of the bill last week, we are both excited and motivated by the opportunity to help patients and validate our business model.”

Oregon Attorney Mike Arnold, founder of Silo Wellness, stated, “We are very excited about the opportunity that Oregon, being the first state to legalize psychedelic mushrooms, presents Silo. Given our experience cultivating and harvested psychedelic mushrooms in Jamaica and our unique metered-dosing delivery mechanism via our patent-pending psilocybin nasal spray, we feel Silo is poised to be an industry leader, not only in Oregon and Jamaica, but in other jurisdictions that will inevitably follow our state’s lead.”

The agenda will be centered on integration in nature after the ketamine sessions using the natural surroundings with a series of memorable elements, including dropping participants off at their cabins via raft after their whitewater mindfulness excursion. Additionally, the waterfall meditation hikes and the total immersion into all the Pacific Northwest has to offer, makes this a unique opportunity for anyone looking to balance mind, body, and spirit while communing with nature.

The pharmacology and physician team have begun offering initial intake consultations for a January 2021 retreat. The Silo Wellness team is also offering this unique opportunity to Oregon physicians working in the ketamine space. “We are looking forward to collaborating with local practitioners to help share with the world the KAP clinical and retreat models,” stated Dr. Aggarwal. “It’s important that we get the word out that these unique treatment alternatives are now available and legal in the United States, and there’s no better way to train than alongside others immersed in the process.”

Silo is collaborating with Portland, Oregon, ketamine clinic operator Dr. Matthew Hicks, ND, MS. Dr. Hicks brings experience in both ketamine therapy and integrative approaches to mental health care.

Silo Wellness is also pleased to announce the engagement of Dave Kopilak, attorney at law, of Emerge Law Group in Portland, who was the primary drafter of Oregon’s newly passed psilocybin law. “Being a resident of Oregon and practicing law here beginning in 2001, I knew the importance of partnering with the top legal professionals in the psychedelic arena,” Arnold stated. “I am pleased to have been working directly with Dave Kopilak and his team on our Oregon ketamine retreat project and look forward to working with them in preparation for Oregon psilocybin therapy. It is certainly a wonderous time to be collaborating with other Oregonians to shape an industry.”

Silo Wellness is Poised to Enter the Oregon Psilocybin Market

With the passing of the Oregon Measure 109, the company intends to offer psilocybin retreats in Oregon as well as pursue a clinical psilocybin-assisted counseling element with patients using the psilocybin nasal spray prior to sessions through either licensees or through the company’s own branded psilocybin service centers. “When I entered the psilocybin space in 2018, I intended to build a company with strong assets ready for what I saw back then as Oregon’s inevitable legalization,” stated Silo Wellness founder Mike Arnold. “With our extensive local Oregon connections, our experience successfully cultivating psychedelic mushrooms in Jamaica since January 2020, our IP portfolio, and now our presence in the psychedelic retreat space in Oregon, we are well positioned to apply for Oregon psilocybin licenses as a company with authentic Oregon roots.”

“While we can’t export our psychedelic mushrooms and truffles from Jamaica, we can export the systems, people, policies, and procedures in order to be turnkey ready in Oregon, the state I have called home for 22 years,” Arnold continued. “We are locked and loaded to meet Silo’s mission to put psychedelics in the hands of people in need as inexpensively and expeditiously as possible. We are blessed to be able refine our psychedelic retreat and cultivation systems in a country a few hundred miles off the coast of the United States and are looking forward to bringing that system to Oregon.”

About Silo Wellness

Silo Wellness is an early mover in the psychedelics and functional mushrooms space. With current operations ongoing in Jamaica for psilocybin cultivation and retreats, the company intends to expand operations and sales to the states and provinces when and if they legalize mushrooms. On August 25, 2020, FlyOverture Equity Inc., operating as Silo Wellness executed an amalgamation agreement with Yukoterre Resources, Inc. (CSE:YT), a company listed on the Canadian Stock Exchange for a go-public transaction via a reverse take-over.

About AIMS Institute

The Advanced Integrative Medical Science Institute, PLLC, of Washington (“AIMS”) (www.aimsinstitute.net) is a leader and early mover in the ketamine-assisted psychotherapy clinic space. Co-founder Dr. Leanna Standish, ND, PhD, LAc, FABNO, is a neuroscientist and naturopathic physician who holds faculty appointments at the University of Washington School of Medicine in the Radiology Department as well as at Bastyr University. She specializes in integrative oncology and neurology. She leads cancer research teams and holds an FDA IND for a phase I clinical trial of ayahuasca, a psychoactive Amazonian tea.  Co-founder Dr. Sunil Aggarwal, MD, PhD, FAAPMR is a Clinical Assistant Professor at the University of Washington School of Medicine, an Affiliate Assistant Professor of Geography at UW, and a Faculty Member of the National Family Medicine Residency. Dr. Aggarwal is also an Associate Member of the New York Academy of Medicine and the Humboldt Institute for Interdisciplinary Marijuana Research. He is also currently an Associate Medical Director of MultiCare Hospice. He serves on the Editorial Advisory Board of the National Cancer Institute’s PDQ Cancer CAM information summary on cannabis and cannabinoids. He has published dozens of peer-reviewed articles and chapters and has been qualified as an expert in cannabis and psilocybin medical and religious use in county, state, and federal courts.

About Dr. Matthew Hicks

Matthew Hicks, ND, MS is a naturopathic physician and holds a degree in integrative medical research. He has published papers on empathy and mindfulness and is completing a certificate in psychedelic therapy and research from the California Institute of Integral Studies. He is the host of the Integrative Psychiatry Review Podcast and founder of Synaptic Integrative Care and Training Institute (https://synaptic.care/) of Portland Oregon, which offers integrative mental health services including ketamine-assisted treatments as well as training on psychedelic therapy. Matthew also happens to be a veteran with a passion for helping other veterans resolve their traumas. He is originally from the Kansas City, Missouri area and attended undergrad at UMKC.

Further Information

For further information, please contact:

Silo Wellness
Mike Arnold, Founder/President
5729 Main St., Suite 148
Springfield, OR 97478
Tel: 541-525-9190
Web: www.SiloWellness.com
Email: press [at symbol] silo wellness [dot com]

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. SILO assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities from Silo Wellness in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Posted on

Silo Wellness Announces the First-of-Its-Kind U.S.-Legal Psychedelic Wellness Nature Retreat in Oregon

SPRINGFIELD, Ore., Nov. 13, 2020 (GLOBE NEWSWIRE) — Oregon’s Silo Wellness (“Silo”), an early mover in the psychedelic mushroom space is pleased to announce that it is organizing a ketamine-assisted wellness retreat in Oregon under the care of Dr. Matthew Hicks, ND, MS. This will add to the existing psilocybin operations in Jamaica, where Silo currently has mushroom and truffle cultivation, as well as multiple psychedelic retreat offerings. In 2019, the company announced its patent-pending psilocybin nasal spray it developed in Jamaica.

Following the landmark passing of Oregon’s Measure 109 authorizing the Oregon Health Authority to permit licensed service providers to administer psilocybin in therapeutic settings (after a two-year rulemaking development period), Silo has positioned itself with a unique alternative to the brick-and-mortar ketamine clinic, similar to the psychedelic retreats it offers in Jamaica.

“We can take our Jamaica psilocybin retreat protocols and use them in Oregon ketamine retreats and then later in Oregon psilocybin retreats once that program is implemented,” explained Silo Director of Science pharmacologist Parag Bhatt, PhD. “This US-based psychedelic retreat model would allow the addition of psilocybin and other natural psychedelics if and when other states come online, similar to the medical marijuana legalization trajectory that began back in 1995 in California.”

The Oregon ketamine-assisted wellness retreat establishes a United States base to meet the needs of those suffering from emotional, spiritual or psychological pain but unable to make a trip to Jamaica to experience legal psilocybin. A short flight from Seattle and San Francisco, and less than a 2.5-hour drive from Portland, Silo’s first Oregon retreat will allow qualifying participants to experience Ketamine-assisted wellness benefits alongside nature. “While ketamine clinics are a convenient and necessary choice for many, psychedelic-enhanced therapy depends a lot on mindset and setting,” said Silo medical advisor and AIMS Clinic of Seattle co-founder Sunil Aggarwal, MD, PhD, FAAPMR. “Traditionally, however, the natural setting has been preferred for those experiencing non-ordinary states of consciousness.”

Silo has engaged experienced ketamine-assisted psychotherapy (KAP) clinic operators Drs. Aggarwal and Leanna Standish, ND, PhD, LAc, FABNO to help develop the screening, retreat agenda, and protocols, as well as research outcomes.

“We welcome the opportunity to activate on this aspect of our business,” stated Douglas Gordon, Silo’s Chief Executive Officer.   “Silo moved early precisely to be in pole position to deliver on these types of experiences and with the passing of the bill last week, we are both excited and motivated by the opportunity to help patients and validate our business model.”

Oregon Attorney Mike Arnold, founder of Silo Wellness, stated, “We are very excited about the opportunity that Oregon, being the first state to legalize psychedelic mushrooms, presents Silo. Given our experience cultivating and harvested psychedelic mushrooms in Jamaica and our unique metered-dosing delivery mechanism via our patent-pending psilocybin nasal spray, we feel Silo is poised to be an industry leader, not only in Oregon and Jamaica, but in other jurisdictions that will inevitably follow our state’s lead.”

The agenda will be centered on integration in nature after the ketamine sessions using the natural surroundings with a series of memorable elements, including dropping participants off at their cabins via raft after their whitewater mindfulness excursion. Additionally, the waterfall meditation hikes and the total immersion into all the Pacific Northwest has to offer, makes this a unique opportunity for anyone looking to balance mind, body, and spirit while communing with nature.

The pharmacology and physician team have begun offering initial intake consultations for a January 2021 retreat. The Silo Wellness team is also offering this unique opportunity to Oregon physicians working in the ketamine space. “We are looking forward to collaborating with local practitioners to help share with the world the KAP clinical and retreat models,” stated Dr. Aggarwal. “It’s important that we get the word out that these unique treatment alternatives are now available and legal in the United States, and there’s no better way to train than alongside others immersed in the process.”

Silo is collaborating with Portland, Oregon, ketamine clinic operator Dr. Matthew Hicks, ND, MS. Dr. Hicks brings experience in both ketamine therapy and integrative approaches to mental health care.

Silo Wellness is also pleased to announce the engagement of Dave Kopilak, attorney at law, of Emerge Law Group in Portland, who was the primary drafter of Oregon’s newly passed psilocybin law. “Being a resident of Oregon and practicing law here beginning in 2001, I knew the importance of partnering with the top legal professionals in the psychedelic arena,” Arnold stated. “I am pleased to have been working directly with Dave Kopilak and his team on our Oregon ketamine retreat project and look forward to working with them in preparation for Oregon psilocybin therapy. It is certainly a wonderous time to be collaborating with other Oregonians to shape an industry.”

Silo Wellness is Poised to Enter the Oregon Psilocybin Market

With the passing of the Oregon Measure 109, the company intends to offer psilocybin retreats in Oregon as well as pursue a clinical psilocybin-assisted counseling element with patients using the psilocybin nasal spray prior to sessions through either licensees or through the company’s own branded psilocybin service centers. “When I entered the psilocybin space in 2018, I intended to build a company with strong assets ready for what I saw back then as Oregon’s inevitable legalization,” stated Silo Wellness founder Mike Arnold. “With our extensive local Oregon connections, our experience successfully cultivating psychedelic mushrooms in Jamaica since January 2020, our IP portfolio, and now our presence in the psychedelic retreat space in Oregon, we are well positioned to apply for Oregon psilocybin licenses as a company with authentic Oregon roots.”

“While we can’t export our psychedelic mushrooms and truffles from Jamaica, we can export the systems, people, policies, and procedures in order to be turnkey ready in Oregon, the state I have called home for 22 years,” Arnold continued. “We are locked and loaded to meet Silo’s mission to put psychedelics in the hands of people in need as inexpensively and expeditiously as possible. We are blessed to be able refine our psychedelic retreat and cultivation systems in a country a few hundred miles off the coast of the United States and are looking forward to bringing that system to Oregon.”

About Silo Wellness

Silo Wellness is an early mover in the psychedelics and functional mushrooms space. With current operations ongoing in Jamaica for psilocybin cultivation and retreats, the company intends to expand operations and sales to the states and provinces when and if they legalize mushrooms. On August 25, 2020, FlyOverture Equity Inc., operating as Silo Wellness executed an amalgamation agreement with Yukoterre Resources, Inc. (CSE:YT), a company listed on the Canadian Stock Exchange for a go-public transaction via a reverse take-over.

About AIMS Institute

The Advanced Integrative Medical Science Institute, PLLC, of Washington (“AIMS”) (www.aimsinstitute.net) is a leader and early mover in the ketamine-assisted psychotherapy clinic space. Co-founder Dr. Leanna Standish, ND, PhD, LAc, FABNO, is a neuroscientist and naturopathic physician who holds faculty appointments at the University of Washington School of Medicine in the Radiology Department as well as at Bastyr University. She specializes in integrative oncology and neurology. She leads cancer research teams and holds an FDA IND for a phase I clinical trial of ayahuasca, a psychoactive Amazonian tea.  Co-founder Dr. Sunil Aggarwal, MD, PhD, FAAPMR is a Clinical Assistant Professor at the University of Washington School of Medicine, an Affiliate Assistant Professor of Geography at UW, and a Faculty Member of the National Family Medicine Residency. Dr. Aggarwal is also an Associate Member of the New York Academy of Medicine and the Humboldt Institute for Interdisciplinary Marijuana Research. He is also currently an Associate Medical Director of MultiCare Hospice. He serves on the Editorial Advisory Board of the National Cancer Institute’s PDQ Cancer CAM information summary on cannabis and cannabinoids. He has published dozens of peer-reviewed articles and chapters and has been qualified as an expert in cannabis and psilocybin medical and religious use in county, state, and federal courts.

About Dr. Matthew Hicks

Matthew Hicks, ND, MS is a naturopathic physician and holds a degree in integrative medical research. He has published papers on empathy and mindfulness and is completing a certificate in psychedelic therapy and research from the California Institute of Integral Studies. He is the host of the Integrative Psychiatry Review Podcast and founder of Synaptic Integrative Care and Training Institute (https://synaptic.care/) of Portland Oregon, which offers integrative mental health services including ketamine-assisted treatments as well as training on psychedelic therapy. Matthew also happens to be a veteran with a passion for helping other veterans resolve their traumas. He is originally from the Kansas City, Missouri area and attended undergrad at UMKC.

Further Information

For further information, please contact:

Silo Wellness
Mike Arnold, Founder/President
5729 Main St., Suite 148
Springfield, OR 97478
Tel: 541-525-9190
Web: www.SiloWellness.com
Email: press [at symbol] silo wellness [dot com]

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. SILO assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities from Silo Wellness in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Posted on

NEONMIND OBTAINS HEALTH CANADA APPROVAL TO ADVANCE PSILOCYBIN RESEARCH

Vancouver, B.C. – November 12, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) is pleased to announce that its majority owned subsidiary NeonMind Biosciences Inc. (“NeonMind”) has obtained Health Canada approval to advance its preclinical trial on psilocybin-based research (the “Trial”).

The Trial is intended to determine the capacity of psilocybin to dose-dependently cause weight loss and prevent weight gain, measuring glucose metabolism, weight loss and effect on food cravings.

NeonMind has engaged the University of British Columbia (the “University”) to conduct the Trial. The services are provided by the University under the supervision of Dr. Alasdair Barr, Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, who is authorized by Health Canada to act as the Principal Investigator for the Trial (the “Principal Investigator”).

Dr. Barr is a tenured faculty member at the University and has extensive experience working with controlled substances as part of his research. His doctoral and post-doctoral research involved a significant body of work using controlled substances.

Before psilocybin, a restricted substance, can be used for a scientific purpose in Canada, the Canadian Minister of Health must grant authority or an exemption pursuant to Subsection 56 of the Controlled Drugs and Substances Act, S.C. 1996, c. 19.

On July 27, 2020, an application regarding the NeonMind Trial was submitted to Health Canada and on October 7, 2020, pursuant to section J.01.059 of Part J of the Food and Drug Regulations (FDR), Health Canada granted authorization to the Principal Investigator to carry out the Trial using psilocybin at UBC.

 

About NeonMind Biosciences Inc.

The NeonMind team marries ancient Ayurvedic wisdom with modern science, delivering high quality formulations that put health and wellness at the forefront for each of its unique coffee blends. In addition to its medicinal mushroom products, NeonMind is developing patent pending intellectual property for therapeutic uses of psilocybin, the psychedelic substance in magic mushrooms. Health Canada has approved NeonMind’s preclinical trial for research into using  psilocybin as a treatment for weight loss and NeonMind is currently developing protocols for Phase II human trials to be submitted for approval in early 2021.

NeonMind’s product candidates with psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (CDSA) and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug.

 

About Better Plant Sciences Inc.

Better Plant Sciences Inc. offers a collection of high-efficacy, plant-based products for optimum health and wellness.  We are a vertically-integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of our products.  We are committed to staying at the forefront of plant-science research and development, and are constantly engaged in research to further expand our portfolio of proprietary formulations and pending patents. Our all natural products vary in use from pain treatment to disease prevention to health optimization, all without chemicals or harmful ingredients.  We have an extensive catalogue of over 400 proprietary product formulas.  We currently have over 80 plant-based products for body, baby, and home for sale through e-commerce or in retail stores under the brands JUSU, Urban Juve, and Wright & Well. Better Plant owns approximately 52% of NeonMind’s issued and outstanding shares.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for Better Plant’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better Plant expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Provides Corporate Update

November 11, 2020 6:00 am Published by 

Novamentis

Vancouver, British Columbia – November 11, 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. (“Pilz”), has provided a corporate update.

Dr. Marvin S. Hausman MD, Chairman and Chief Scientific Officer of Pilz commented: “We are very pleased with the progress that we have made to date in advancing our scientific research mandate relating to our investigations into Autism Spectrum Disorder (ASD) and the potential for psilocybin and tryptamine-based compounds to be used in the treatment of this unmet medical need.”   He continued: “To this end, we have accomplished a number of initial milestones which, we believe, will assist in setting the stage for our future scientific and commercial advancement.”
Achievements to date include:

Pilz Sponsored Cell Study:

  • The goal for this initial study was to test Psilocybin and Psilocin for cellular bioavailability in a preclinical bioassay.
  • It was found that both Psilocin and Psilocybin had antioxidant capacity, with Psilocin being superior to Psilocybin.
  • Psilocin clearly showed a significant cellular antioxidant protection of red blood cells, as it robustly reduced the intracellular oxidative stress in the CAP-e bioassay.

Master Services Agreement:

  • Pilz entered into a Master Services Agreement (MSA) with Comac Medical Ltd. (“Comac”).  Comac is an international clinical research/site management company based in Sophia, Bulgaria that is engaged in clinical trial monitoring, bioanalysis, GxP auditing, and biometrics.
  • Comac will assist Pilz in designing and performing pharmacokinetic and Phase 1 clinical studies, as well as assist in European regulatory filings for drug approval.

Initiation of Pre-Clinical Study in Autism Spectrum Disorder:

  •  Dr. Viviana Trezza at Roma Tre University (Rome, Italy) has developed a rat model that allows the evaluation of the relationship between altered brain function in Autism Spectrum Disorder and behavior.
  • This unique animal model assists in unraveling the relationship between altered brain function in ASD and behavior and will allow Pilz to test its new psychedelic pharmaceutical compounds.
  • An initial non-treatment behavioral study was completed in September, 2020, and collected biologic samples are undergoing molecular and bacteriologic analysis. The results from these state-of-the-art analytics will be used to develop a unique proprietary diagnostic and therapeutic paradigm, titled the “Pilz ASD Correlate.” This “ASD Correlate” will be used in preclinical and clinical models to test the therapeutic application of the psilocybin and tryptamine derivatives under development, as well as personalize individual ASD therapy.

Proprietary Psilocybin Manufacturing Agreement:

  • Pilz entered into a psilocybin and tryptamine derivative manufacturing agreement with a U.S. based pharmaceutical company with over 800 employees.
  • Pilz is working closely with the manufacturing chemists to design a proprietary synthetic pathway that will allow possible patent filing.
  • Pilz will have complete and sole ownership of the Drug Master File (DMF) which will be used for regulatory submission prior to commencing human clinical trials.  Initial jurisdictions under consideration include the United States, Canada, and the European Union.
  • NonGMP psilocybin is being manufactured for shipment to Dr. Trezza’s lab in Italy to start treatment of ASD afflicted rats in a scientifically accepted research study. All export and import licenses are being readied for shipment of this schedule 1 controlled research drug.

Upcoming Deliverables and Milestones for Q4, 2020:

  • The initial phase of the behavioral pre-clinical ASD study at Roma Tre University has been completed and Pilz is awaiting molecular, biochemical and bacteriologic results from its contracted labs, Microbiome Insights, University of British Columbia, Vancouver, Canada and Thermo Fisher Scientific, Vienna, Austria. A deep learning artificial intelligence program for ASD will be developed that integrates inflammation, oral/gut/brain axis, and behavior.
  • A rat ASD preclinical study with treatment and control groups has been designed and psilocybin dosage amounts will be established using the currently manufactured Pilz psilocybin. Behavioral modification and side effects will also be assessed.

 

Pharmacokinetic studies are being designed and the data will lay the groundwork for potential Pilz regulatory submissions for human research.

NOVA’s pending acquisition of Pilz is subject to requisite regulatory approval, as applicable, and receipt of requisite approval of Pilz shareholders.

About Pilz Bioscience Corp.

Pilz Bioscience Corp. (“Pilz”) is a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs. The initial focus is on Autism Spectrum Disorder (ASD). The company intends to leverage a unique systems-level scientific approach that integrates inflammation, oral/gut/brain axis, and behavior. Pilz aims to lead the global effort in design of effective and comprehensive diagnostic/monitoring programs and first-in-class therapeutics.
https://pilzbioscience.com/

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. (formerly Liberty Leaf Holdings Ltd.) is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, an Okanagan BC based, Health Canada Standard Licensed facility focused on the cultivation of premium, small batch Kush dominant cultivars.

For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca

On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

Posted on

Novamind Supports Oregon Measure 109 to Responsibly Expand Patient Access to Psilocybin Therapy

Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

TORONTO, ON / ACCESSWIRE / November 10, 2020 / Novamind Ventures Inc. (“Novamind”), a leading mental health and wellness company specialized in psychedelic-assisted psychotherapy, today announced its support for the recently passed Measure 109 in the State of Oregon, a citizen initiative to establish the first regulated and licensed program for psilocybin therapy in the United States.

“The passage of Measure 109 is a major milestone in the movement to regulate psychedelic medicine, and it paves the way for patients in Oregon and beyond to access psilocybin therapy in a safe and legal manner,” said Yaron Conforti, Chief Executive Officer and Director of Novamind. “We support responsible and measured initiatives to expand access to psychedelic medicine and look forward to working with healthcare professionals and key stakeholders in Oregon to contribute to The Psilocybin Mushroom Service Program for the ultimate benefit of patients seeking safe and regulated access to alternative mental health therapies.”

Novamind has clinical expertise in psychedelic-assisted psychotherapy that can enable the planning and execution of psilocybin treatments in Oregon, and across the country. Novamind clinicians are widely recognized for participation in leading clinical trials examining psychedelics, as well as their capabilities in delivering safe, legal experiences for patients utilizing ketamine in the United States. Cedar Psychiatry by Novamind, based in Utah, has administered over 3,000 ketamine-assisted psychotherapy treatments since 2016 across its four clinics in the State.

With the passing of Measure 109, the Oregon Health Authority is now authorized to create a program, subject to a two-year development timeline, that permits licensed service providers to administer psilocybin-producing mushroom and fungi products to individuals 21 years of age or older. Psilocybin will not be available commercially or for home-based use, and strict regulations ensure psilocybin will only be used in settings under the supervision of trained facilitators.

About Novamind

Novamind is building a global network of clinics, retreats and research sites to serve the regulated psychedelics industry. With our wholly-owned subsidiaries, Cedar Psychiatry and Cedar Clinical Research, Novamind is dedicated to providing access to safe and legal psychedelic experiences, while advancing research for psychedelic medicine.

For more information visit www.novamind.ca.

Contact Information

Novamind
Yaron Conforti, CEO and Director
T: +1 (647) 953 9512
E: contact@novamind.ca

Posted on

Nova Mentis Life Science Acquisition Target, Pilz Bioscience Corp, Signs Psilocybin Manufacturing Agreement

November 5, 2020 6:30 am Published by 

Novamentis

Vancouver, British Columbia – November 5, 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”) is pleased to announce that its pending acquisition target, Pilz Bioscience Corp. (“Pilz”), has entered into a psilocybin manufacturing agreement with a U.S. based pharmaceutical company with over 800 employees. Pilz will have complete and sole ownership of the Drug Master File (DMF) which will be used for regulatory submission prior to commencing human clinical trials.  Initial jurisdictions under consideration include United States, Canada and the European Union. Pilz is working closely with the manufacturing chemists to design a  proprietary synthetic pathway that will allow possible patent filing.

Pilz is a research and development driven biotechnology company that aims to develop medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs.  Pilz’s focus is on Autism Spectrum Disorder (ASD), and its initial research has centred on developing a unique and proprietary system for diagnosing and treating ASD, with first-in-class psilocybin-based therapeutics.

Pilz plans to use the manufactured psilocybin product in its upcoming study at Roma Tre University, Rome, Italy.  The study is being led by the well-regarded research neuroscientist, Dr. Viviana Trezza, Head of Pharmacology.  Dr. Trezza has developed a rat model of ASD that has been recognized and accepted by  the neurologic scientific community.

Autism Marketplace

Autism refers to a range of conditions characterized by challenges with social skills, repetitive behaviours, speech and nonverbal communication. There is not one singular type of autism but many types, caused by different combinations of genetic and environmental influences. The term “spectrum” reflects the wide variation in challenges and strengths possessed by each person with autism.

The intensity and severity of the disease is different with each individual with the diagnosis of autism generally starting at a very young age in children 2-3 years of age. The cause of the disease has yet to be determined, but research continues to find new methods and pharmaceutical regimes to control the disease with the goal of finding an eventual cure. While no one therapy or drug has proved to be completely effective, psilocybin’s ability to open up a patient’s perspective and view on life is beginning to gain momentum in the research community and new studies are underway on their effectiveness and proven success with helping autistic adults.

In September 2020, Data Bridge Market Research issued a report titled The Global Autism Therapy Market and has forecasted the market’s rise from its  initial value of USD 5.62 billion in 2018 to an estimated value of USD 7.85 billion by 2026, registering a CAGR of 4.25% in the forecast period of 2019-2026.

Data Bridge Market Research concludes the increase in market value can be attributed to the rising awareness about the disease and its prevalence in the market.

About Pilz Bioscience Corp.

Pilz Bioscience Corp. (“Pilz”) is a biotechnology company developing medicinal psychedelics for neuroinflammatory conditions with a significant cognitive component and high unmet therapeutic needs. The initial focus is on Autism Spectrum Disorder (ASD). The company intends to leverage a unique systems-level scientific approach that integrates inflammation, oral/gut/brain axis, and behavior. Pilz aims to lead the global effort in design of effective and comprehensive diagnostic/monitoring programs and first-in-class therapeutics.
https://pilzbioscience.com/

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. (formerly Liberty Leaf Holdings Ltd.) is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, an Okanagan BC based, Health Canada Standard Licensed facility focused on the cultivation of premium, small batch Kush dominant cultivars.
NOVA’s pending acquisition of Pilz is subject to requisite regulatory approval, as applicable, and receipt of requisite approval of Pilz shareholders.

For further information on the Company, please visit https://www.novamentis.ca or email info@novamentis.ca

On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
Phone: 778-819-0244
Toll Free: 1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislscFacebook: @novamentislsc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

FacebookTwitterLinkedInEmailShare